IT-FC 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections caused by susceptible organisms, including dermatophytes, yeasts, and molds. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This disruption compromises membrane integrity, leading to fungal cell death. IT-FC 200 Capsule is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. The capsule formulation ensures optimal bioavailability when taken with food, enhancing systemic absorption. Dosage and duration of therapy depend on the type and severity of infection, and treatment should be guided by clinical response and laboratory findings. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully evaluated due to itraconazole’s effect on cytochrome P450 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and elevated liver enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy to ensure patient safety.